Immunetune is a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases. Its proprietary set of technologies allow the rapid, cell-free generation of personalized cancer vaccines encoding multiple (neo-)antigens in linear synthetic DNA with improved immunogenicity through its unique PyroVant™ adjuvant. Its lead cancer vaccine has achieved preclinical Proof of Concept in animal studies and is finalizing its preclinical package with the aim to initiate clinical studies in 2022. Immunetune’s pipeline further consists of infectious disease vaccines, including a pan-corona DNA vaccine, targeting conserved proteins across multiple strains of coronaviruses for global pandemic readiness, currently in preclinical testing.